Dr. Wojciech Jurczak on MOR208 in Non-Hodgkin's Lymphoma

​Wojciech Jurczak, MD
Published: Saturday, Jun 11, 2016



Wojciech Jurczak, MD Head of Lymphoma, Department of Hematology, Jagiellonian University, Kopernika, Poland, discuses a subgroup analyses of diffuse large b-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).
 
MOR208, a monoclonal antibody directed against the antigen CD19, was given to patients for at least 3 months. In the DLBCL subgroup a 30% objective response rate was achieved, with most responses being durable and some continuing beyond 2-years. MOR208 is a relatively non-toxic treatment and a potential target for future combinations regimens, said Jurczak. The 30% response rate was more than expected, he says.
 
In the indolent lymphoma cohort, the protocol was poorly designed, says Jurczak. Most of the patients responded, however nearly half had stable disease and as such therapy was not continued after the first cycle. Those who responded did have a prolonged progression-free-survival, he says.

<<< View more from the 2016 EHA Congress


Wojciech Jurczak, MD Head of Lymphoma, Department of Hematology, Jagiellonian University, Kopernika, Poland, discuses a subgroup analyses of diffuse large b-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).
 
MOR208, a monoclonal antibody directed against the antigen CD19, was given to patients for at least 3 months. In the DLBCL subgroup a 30% objective response rate was achieved, with most responses being durable and some continuing beyond 2-years. MOR208 is a relatively non-toxic treatment and a potential target for future combinations regimens, said Jurczak. The 30% response rate was more than expected, he says.
 
In the indolent lymphoma cohort, the protocol was poorly designed, says Jurczak. Most of the patients responded, however nearly half had stable disease and as such therapy was not continued after the first cycle. Those who responded did have a prolonged progression-free-survival, he says.

<<< View more from the 2016 EHA Congress

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x